Liminatus Pharma (LIMN) said Friday it is exploring the formation of a $500 million digital asset investment subsidiary.
The proposed subsidiary, if approved, would operate separately from Liminatus's core clinical pipeline and focus on digital asset allocation and blockchain-integrated financial structures, the company said.
Liminatus said potential capital formation could involve private placements, convertible instruments, equity line, and other structured financing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。